Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02386423 · ClinicalTrials.gov registry record · NA
RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome
A NA study of Restless Leg Syndrome, sponsored by Lake Erie Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02386423: Completed NA study of Restless Leg Syndrome, sponsored by Lake Erie Research Institute.
NCT02386423 is a NA study of Restless Leg Syndrome that has completed, run by Lake Erie Research Institute. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02386423, a NA study of Restless Leg Syndrome, has completed, sponsored by Lake Erie Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and efficacy of RESTIFFIC™, a foot wrap that produces adjustable targeted pressure on specific muscles in the feet, to reduce the symptoms of moderate to severe primary Restless Legs Syndrome.
Conditions Studied
Interventions
- DEVICE RESTIFFIC™ Brand Pressure Application System
Study Locations (1)
Pennsylvania
- Baycity Associated in Podiatry Inc - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02386423
The ClinicalTrials.gov registry entry for NCT02386423 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lake Erie Research Institute, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Restless Leg Syndrome appearing as the primary indexed condition, and to 1 intervention - of which RESTIFFIC™ Brand Pressure Application System is the first listed.
NCT02386423 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02386423 about?
NCT02386423 is a clinical study titled "RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome". The purpose of this study is to determine the safety and efficacy of RESTIFFIC™, a foot wrap that produces adjustable targeted pressure on specific muscles in the feet, to reduce the symptoms of moderate to severe primary Restless Legs Syndrome.
What is the current status of trial NCT02386423?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2009-04. Estimated completion is 2011-11.
What conditions does trial NCT02386423 study?
This clinical trial studies the following conditions: Restless Leg Syndrome.
What interventions are being tested in trial NCT02386423?
The interventions under investigation include: RESTIFFIC™ Brand Pressure Application System (DEVICE).
Who is sponsoring clinical trial NCT02386423?
This trial is sponsored by Lake Erie Research Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02386423 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Leg Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.